I've stated it several times that I hold a similar view.
To me this is currently well over-valued (i.e. too much forward earnings priced in) compared to other biotech companies I have reviewed. Sure it may go up on another announcement (which doesn't automatically add tangible sales I might add..) but i'll take that risk.
I hope for the holders sake that it does go up, I really do, but I'm (mostly) a value investor so I will buy this when I think its value proposition is better.